A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336

被引:1
|
作者
Carroll, F. Ivy [1 ]
Kosten, Thomas R. [2 ]
Buda, Jeffrey J. [1 ]
Wang, Laurene [3 ]
Walters, Bradford B. [1 ]
机构
[1] RTI Int, Res Triangle Pk, NC 27709 USA
[2] Baylor Coll Med, Psychiat Neurosci Pharmacol & Immunol & Pathol, Houston, TX 77030 USA
[3] INDApharma, Chapel Hill, NC USA
来源
关键词
RTI-336; dopamine transporter inhibitor; Clinical Trials; cocaine dependence; addiction and addiction behaviors; pharmacokinetics and drug metabolism (PDM); safety; tolerability; COCAINE USE DISORDER; DOPAMINE TRANSPORTER; NONHUMAN-PRIMATES; SQUIRREL-MONKEYS; RHESUS-MONKEYS; ABUSE; ANALOGS; DRUGS; PHARMACOTHERAPY; INHIBITORS;
D O I
10.3389/fphar.2018.00712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Preclinical and clinical data suggest that a compound which binds potently to and inhibits the dopamine transporter, but with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity, could be a useful adjunct in the treatment of cocaine dependence. Methods: We assessed the safety, tolerability, and pharmacokinetics (PK) of oral single doses (0.3, 1, 3, 6, 12, and 20 mg) of such an analog, RTI-336, in a randomized, double-blind, and placebo-controlled trial in healthy adult males. Pre-dose and post-dose safety assessments included physical examinations (including neurological examination); orthostatic vital signs; 6-lead continuous electrocardiogram (ECG) telemetry monitoring pre-dose to 8 h post-dose; 12-lead ECGs; clinical chemistry, hematology, and urinalysis; mini mental status examinations; and adverse events. RTI-336 PK was assessed in plasma and urine. Results: 22 participants were enrolled. RTI-336 was well-tolerated up to the maximum evaluated dose of 20 mg. PK analyses demonstrated good absorption with peak plasma maximum concentrations (C-max) occurring around 4 h post-dose and consistent half-lives of around 17 h for the 6, 12, and 20 mg doses. Plasma drug exposure and Cmax increased in proportion to dose. Only 0.02% of RTI-336 excreted was unchanged in urine. Active metabolites UC-M5, UC-M8, and UC-M2 were measurable in plasma and urine, with plasma Cmax of UC-M5 and UC-M8 exceeding that of RTI-336. Three AE possibly were related to RTI-336 and resolved with discontinuation; the one serious AE was unrelated to RTI-336. 2 participants had transient and mild serum total bilirubin elevations (< 1.5 x upper limit of normal) at day 3 post-dose which resolved by day 8 post-dose. Conclusion: All doses including the highest (20 mg) showed excellent safety and tolerability, and further studies in humans are warranted.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects A Randomized, Double-Blind, Placebo-Controlled, Phase I Study
    Derks, Michael
    Anzures-Cabrera, Judith
    Turnbull, Lynn
    Phelan, Mary
    CLINICAL DRUG INVESTIGATION, 2011, 31 (05) : 325 - 335
  • [22] Safety and tolerability of Ganoderma lucidum in healthy subjects:: A double-blind randomized placebo-controlled trial
    Wicks, Sheila M.
    Tong, Robin
    Wang, Chong-Zhi
    O'Connor, Michael
    Karrison, Theodore
    Li, Shang
    Moss, Jonathan
    Yuan, Chun-Su
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2007, 35 (03): : 407 - 414
  • [23] Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Klein, David J.
    Battelino, Tadej
    Chatterjee, D. J.
    Jacobsen, Lisbeth V.
    Hale, Paula M.
    Arslanian, Silva
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (10) : 679 - 687
  • [24] A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CB03-154 in Healthy Subjects
    Zhu, Minjuan
    Hua, Bo
    Li, Baini
    Guo, Ruoling
    Liu, Gang
    Liu, Xiuxiu
    Wan, Hui
    Yao, Shuran
    Song, Chao
    Dou, Jinhui
    Zhang, Xin
    Lu, Zhihong
    Zhou, Xiaolin
    Chen, Huanming
    Gonen, Ofer
    ANNALS OF NEUROLOGY, 2024, 96 : S179 - S180
  • [25] A single-center, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of multiple-ascending doses of pridopidine in healthy volunteers
    Osterberg, O.
    Ivkovic, J.
    Sundgreen, C.
    Muglia, P.
    Prang, A.
    Darpo, B.
    NEUROTHERAPEUTICS, 2013, 10 (01) : 175 - 175
  • [26] Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial
    Linder, Steven L.
    Mathew, Ninan T.
    Cady, Roger K.
    Finlayson, Gary
    Ishkanian, Gary
    Lewis, Donald W.
    HEADACHE, 2008, 48 (09): : 1326 - 1336
  • [27] SAFETY AND TOLERABILITY OF ADJUNCTIVE BRIVARACETAM IN ADULTS WITH UNCONTROLLED EPILEPSY: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Kwan, P.
    Johnson, M. E.
    Merschhemke, M.
    Lu, S.
    EPILEPSIA, 2010, 51 : 152 - 152
  • [28] Safety and Tolerability of Two Doses of Simvastatin Associated with Rifaximin in Patients with Decompensated Cirrhosis. a Double-Blind, Randomized, Placebo-Controlled Trial
    Elisa, Pose
    Napoleone, Laura
    Amin, Ahmed
    Campion, Daniela
    Jimenez, Cesar
    Piano, Salvatore
    Roux, Olivier
    Uschner, Frank Erhard
    Wit, De Koos
    Zaccherini, Giacomo
    Alessandria, Carlo
    Angeli, Paolo
    Bernardi, Mauro
    Beuers, Ulrich
    Caraceni, Paolo
    Durand, Francois
    Mookerjee, Rajeshwar P.
    Trebicka, Jonel
    Vargas, Victor
    Carol, Marta
    Pich, Judit
    Domenech, Gema
    Casanovas, Georgina
    Torres, Ferran
    Gines, Pere
    HEPATOLOGY, 2018, 68 : 176A - 176A
  • [29] Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies of the Safety, Tolerability and Pharmacokinetics of Naldemedine in Healthy Volunteers
    Fukumura, Kazuya
    Yokota, Takaaki
    Baba, Yuko
    Camilo, Juan
    Ferreira, Arjona
    GASTROENTEROLOGY, 2016, 150 (04) : S537 - S538
  • [30] Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers
    Fukumura, Kazuya
    Yokota, Takaaki
    Baba, Yuko
    Ferreira, Juan Camilo Arjona
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (05): : 474 - 483